巨细胞动脉炎中糖皮质激素的降低。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-06-13 DOI:10.1016/j.medj.2025.100744

Tanaz A Kermani, Kenneth J Warrington

{"title":"巨细胞动脉炎中糖皮质激素的降低。","authors":"Tanaz A Kermani, Kenneth J Warrington","doi":"10.1016/j.medj.2025.100744","DOIUrl":null,"url":null,"abstract":"Giant cell arteritis is a large-vessel vasculitis affecting the aorta and its branches. While treatment with glucocorticoids is efficacious in the initial management, patients experience relapses and adverse effects. The results of a clinical trial evaluating upadacitinib for treatment of giant cell arteritis have been published.1 Here, we review the data and the implications for patients with this condition.","PeriodicalId":29964,"journal":{"name":"Med","volume":"6 6","pages":"100744"},"PeriodicalIF":12.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"JAKing down glucocorticoids in giant cell arteritis.\",\"authors\":\"Tanaz A Kermani, Kenneth J Warrington\",\"doi\":\"10.1016/j.medj.2025.100744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Giant cell arteritis is a large-vessel vasculitis affecting the aorta and its branches. While treatment with glucocorticoids is efficacious in the initial management, patients experience relapses and adverse effects. The results of a clinical trial evaluating upadacitinib for treatment of giant cell arteritis have been published.1 Here, we review the data and the implications for patients with this condition.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"6 6\",\"pages\":\"100744\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2025.100744\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2025.100744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

巨细胞动脉炎是一种影响主动脉及其分支的大血管炎。虽然糖皮质激素治疗在初始治疗中是有效的，但患者会经历复发和不良反应。一项评估upadacitinib治疗巨细胞动脉炎的临床试验结果已经发表在这里，我们回顾了数据和对患有这种疾病的患者的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

JAKing down glucocorticoids in giant cell arteritis.

Giant cell arteritis is a large-vessel vasculitis affecting the aorta and its branches. While treatment with glucocorticoids is efficacious in the initial management, patients experience relapses and adverse effects. The results of a clinical trial evaluating upadacitinib for treatment of giant cell arteritis have been published.¹ Here, we review the data and the implications for patients with this condition.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.